Recommendations for the management of COVID 19 patients regarding proarrhythmic effects of some current treatments, specifically if these patients suffer from arrhythmias, and for those receiving antiarrhythmic therapy.

Ardashev Av, Oscar Oseroff, Rodolfo Sansalone, Evgeny G. Zhelyakov, Riccardo Cappato, V. А. Snezhitskiy, С. Г. Канорский, S. Abzalieva S. Abzalieva, Yu. N. Belenkov, Yury Karpenko

6 more authors

Aras Puodžiūkynas, S. A. Sayganov, Luca Santini, Ricardo Speranza, Marina Yakovleva, Ludmila Kolotsey

2020

Full text Open access: Hybrid Metadata (CSL-JSON)

DOI 10.18087/cardio.2020.10.n1283

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Recommendation provides information to employees of medical departments at any level and primarily primary care about the possible proarrhythmic and adverse effects of drugs used for the treatment of COVID-19 patients and the features of therapy for COVID-19 patients with heart rhythm and conduction disorders receiving permanent antiarrhythmic therapy.